Sold all my CYTK the day after the R/S at $12.15 avg and avoided a big loss. Some on this board said ETRM was junk, but is up 14% since my 8/14 buy recommendation. Check my posts on the ETRM board: my ONLY ID since 2006 is DCTRIG.
Cancunfish: Good to hear from you again. The important future question will be whether Amgen likes CYTK. Posters on this board have no sense of the rigorous process Amgen will put OM through before committing to phase III trials. I'd say the prospects are 50/50 at best.